Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein

Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein

Canocapavir is a novel antiviral agent with characteristics of core protein allosteric modulators (CpAMs) that is currently in a phase II clinical trial for treatment of hepatitis B virus (HBV) infection. Herein, we show that Canocapavir prevented the encapsidation of HBV pregenomic RNA and increase...

Full description

Bibliographic Details
Main Authors: Yuan Zheng, Le Yang, Lin Yu, Yuanfei Zhu, Yang Wu, Zhijun Zhang, Tian Xia, Qiang Deng
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Viruses
Subjects:
hepatitis B virus
hepatitis B virus core protein
core protein allosteric modulator
capsid assembly
viral particle egress
allosteric effect
Online Access:https://www.mdpi.com/1999-4915/15/5/1195

Internet

https://www.mdpi.com/1999-4915/15/5/1195

Similar Items